Published in J Clin Invest on April 01, 2003
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 4.51
Complement regulators and inhibitory proteins. Nat Rev Immunol (2009) 4.46
Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A (2006) 3.80
A rare penetrant mutation in CFH confers high risk of age-related macular degeneration. Nat Genet (2011) 3.55
Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med (2009) 3.24
Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet (2006) 3.24
The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol (2007) 3.12
Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet (2005) 2.92
Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet (2007) 2.79
Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A (2003) 2.79
Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med (2007) 2.55
Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol (2008) 2.19
Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol (2008) 1.99
Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet (2003) 1.92
Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol (2008) 1.89
STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol (2012) 1.89
The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol (2010) 1.88
Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet (2013) 1.77
Platelet activation leads to activation and propagation of the complement system. J Exp Med (2005) 1.76
Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J (2006) 1.72
Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol (2008) 1.68
Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol (2010) 1.68
aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol (2010) 1.67
Genetics and complement in atypical HUS. Pediatr Nephrol (2010) 1.64
The alternative complement pathway revisited. J Cell Mol Med (2008) 1.62
Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci U S A (2011) 1.58
Atypical hemolytic uremic syndrome. Semin Nephrol (2013) 1.56
Translational mini-review series on complement factor H: structural and functional correlations for factor H. Clin Exp Immunol (2008) 1.52
Complement System Part I - Molecular Mechanisms of Activation and Regulation. Front Immunol (2015) 1.52
C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest (2013) 1.52
The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin Exp Immunol (2006) 1.50
Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant (2012) 1.44
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood (2014) 1.42
Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. Am J Pathol (2005) 1.40
Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation. Blood (2017) 1.39
Identification of a rare coding variant in complement 3 associated with age-related macular degeneration. Nat Genet (2013) 1.39
Mutations in FN1 cause glomerulopathy with fibronectin deposits. Proc Natl Acad Sci U S A (2008) 1.37
Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2013) 1.32
Complement System Part II: Role in Immunity. Front Immunol (2015) 1.31
The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol (2008) 1.31
Dense deposit disease. Mol Immunol (2011) 1.31
Overview of complement activation and regulation. Semin Nephrol (2013) 1.26
The hyphal and yeast forms of Candida albicans bind the complement regulator C4b-binding protein. Infect Immun (2004) 1.25
Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. J Biol Chem (2009) 1.21
Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol (2005) 1.19
Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov (2015) 1.16
Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities. J Biol Chem (2011) 1.15
The C-terminus of complement factor H is essential for host cell protection. Mol Immunol (2007) 1.14
Complement regulator Factor H mediates a two-step uptake of Streptococcus pneumoniae by human cells. J Biol Chem (2010) 1.13
Complement activation, regulation, and molecular basis for complement-related diseases. EMBO J (2015) 1.12
Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions. J Immunol (2013) 1.06
Atypical haemolytic uraemic syndrome and mutations in complement regulator genes. Springer Semin Immunopathol (2005) 1.05
DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome. Pediatr Nephrol (2010) 1.05
Genetic variants in the complement system predisposing to age-related macular degeneration: a review. Mol Immunol (2014) 1.04
Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity. J Immunol (2009) 1.03
The complotype: dictating risk for inflammation and infection. Trends Immunol (2012) 1.03
Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome. Mol Immunol (2006) 1.03
Whole-exome sequencing identifies rare, functional CFH variants in families with macular degeneration. Hum Mol Genet (2014) 1.00
Complement in glomerular injury. Semin Immunopathol (2007) 0.99
Factor h: a complement regulator in health and disease, and a mediator of cellular interactions. Biomolecules (2012) 0.99
The role of complement in age-related macular degeneration: heparan sulphate, a ZIP code for complement factor H? J Innate Immun (2013) 0.96
New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3. Biosci Rep (2014) 0.96
Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign? J Am Soc Nephrol (2014) 0.95
Annexin-II, DNA, and histones serve as factor H ligands on the surface of apoptotic cells. J Biol Chem (2009) 0.92
Release of endogenous anti-inflammatory complement regulators FHL-1 and factor H protects synovial fibroblasts during rheumatoid arthritis. Clin Exp Immunol (2003) 0.88
Challenges in the management of infantile factor H associated hemolytic uremic syndrome. Pediatr Nephrol (2004) 0.88
Analysis of rare variants in the C3 gene in patients with age-related macular degeneration. PLoS One (2014) 0.87
Properdin and factor h: opposing players on the alternative complement pathway "see-saw". Front Immunol (2013) 0.87
The glomerular filtration barrier: components and crosstalk. Int J Nephrol (2012) 0.87
Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy. J Immunol (2013) 0.86
Complement system on the attack in autoimmunity. J Clin Invest (2003) 0.86
ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura. Eur J Pediatr (2006) 0.86
Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome. Immunobiology (2011) 0.85
Pathogenesis and prognosis of thrombotic microangiopathy. Clin Exp Nephrol (2007) 0.84
Molecular characterization of the interaction between sialylated Neisseria gonorrhoeae and factor H. J Biol Chem (2011) 0.83
Role of Factor H and Related Proteins in Regulating Complement Activation in the Macula, and Relevance to Age-Related Macular Degeneration. J Clin Med (2015) 0.83
Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases. J Am Soc Nephrol (2015) 0.82
Factor H in porcine seminal plasma protects sperm against complement attack in genital tracts. J Biol Chem (2009) 0.80
Analysis of rare variants in the CFH gene in patients with the cuticular drusen subtype of age-related macular degeneration. Mol Vis (2015) 0.80
Dissection of functional sites in herpesvirus saimiri complement control protein homolog. J Virol (2012) 0.78
Alternative Pathway Dysregulation and the Conundrum of Complement Activation by IgG4 Immune Complexes in Membranous Nephropathy. Front Immunol (2016) 0.77
Lack of association between polymorphisms in C4b-binding protein and atypical haemolytic uraemic syndrome in the Spanish population. Clin Exp Immunol (2009) 0.77
Complement factor H R1210C among Japanese patients with age-related macular degeneration. Jpn J Ophthalmol (2015) 0.77
A Novel Factor H-Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae. J Immunol (2016) 0.77
The Genetics of Ultra-Rare Renal Disease. J Pediatr Genet (2016) 0.77
Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH/CFHR1-3 and complement factor H 479. Blood Transfus (2013) 0.76
Autoimmunity: homeostasis of innate immunity gone awry. J Clin Immunol (2012) 0.76
Glomerular basement membrane heparan sulfate in health and disease: A regulator of local complement activation. Matrix Biol (2016) 0.76
Mutations in Complement Factor H Impair Alternative Pathway Regulation on Mouse Glomerular Endothelial Cells in Vitro. J Biol Chem (2016) 0.76
Circulating microRNAs in patients with Shiga-Toxin-producing E. coli O104:H4 induced hemolytic uremic syndrome. PLoS One (2012) 0.76
Minor Role of Plasminogen in Complement Activation on Cell Surfaces. PLoS One (2015) 0.75
Mapping rare, deleterious mutations in Factor H: Association with early onset, drusen burden, and lower antigenic levels in familial AMD. Sci Rep (2016) 0.75
The complement system in age-related macular degeneration: A review of rare genetic variants and implications for personalized treatment. Mol Immunol (2016) 0.75
Highly penetrant alleles in age-related macular degeneration. Cold Spring Harb Perspect Med (2014) 0.75
Genetic kidney diseases in the pediatric population of southern Israel. Pediatr Nephrol (2006) 0.75
THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET. Retina (2016) 0.75
Modulation of the alternative complement pathways by beta 1 H globulin. J Exp Med (1976) 7.00
Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int (1998) 4.03
Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet (2001) 2.92
Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet (2001) 2.75
The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol (2001) 2.56
Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am J Hum Genet (2002) 2.29
Identification of complement regulatory domains in human factor H. J Immunol (1995) 2.02
Mapping of the complement regulatory domains in the human factor H-like protein 1 and in factor H1. J Immunol (1995) 1.99
The factor H protein family. Immunopharmacology (1999) 1.96
Identification of the second heparin-binding domain in human complement factor H. J Immunol (1998) 1.92
Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. Proc Natl Acad Sci U S A (1996) 1.91
Hemolytic uremic syndrome in families. N Engl J Med (1975) 1.84
The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol (1998) 1.83
Each of the three binding sites on complement factor H interacts with a distinct site on C3b. J Biol Chem (2000) 1.82
Hypocomplementaemia due to a genetic deficiency of beta 1H globulin. Clin Exp Immunol (1981) 1.80
Complement factor H and the haemolytic uraemic syndrome. Lancet (2001) 1.74
Cutting edge: localization of the host recognition functions of complement factor H at the carboxyl-terminal: implications for hemolytic uremic syndrome. J Immunol (2002) 1.69
Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. J Am Soc Nephrol (1999) 1.53
Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. J Biol Chem (1997) 1.48
Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J Biol Chem (2000) 1.46
Mapping of the domains required for decay acceleration activity of the human factor H-like protein 1 and factor H. Eur J Immunol (1996) 1.46
The baculovirus expression vector pBSV-8His directs secretion of histidine-tagged proteins. Gene (1995) 1.44
The C-terminus of factor H: monoclonal antibodies inhibit heparin binding and identify epitopes common to factor H and factor H-related proteins. Biochem J (1998) 1.40
Molecular modelling of the C-terminal domains of factor H of human complement: a correlation between haemolytic uraemic syndrome and a predicted heparin binding site. J Mol Biol (2002) 1.34
Kinetic and thermodynamic analysis of the control of C3b by the complement regulatory proteins factors H and I. Biochemistry (1983) 1.30
Human polymorphonuclear leukocytes adhere to complement factor H through an interaction that involves alphaMbeta2 (CD11b/CD18). J Immunol (1998) 1.23
Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet (2000) 1.23
Hemolytic uremic syndrome: how do factor H mutants mediate endothelial damage? Trends Immunol (2001) 1.19
The hemolytic-uremic syndrome is a syndrome. N Engl J Med (1978) 1.19
The hemolytic uremic syndrome. Kidney Int Suppl (1998) 1.11
Complement factor H and hemolytic uremic syndrome. Int Immunopharmacol (2001) 1.10
Factor H and disease: a complement regulator affects vital body functions. Mol Immunol (1999) 1.09
Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction or removal of overlying endothelial cells. J Immunol (1998) 0.99
Complement C3b interactions studied with surface plasmon resonance technique. Int Immunopharmacol (2001) 0.99
The complement system in hemolytic-uremic syndrome in childhood. Clin Nephrol (1980) 0.92
Familial relapsing haemolytic uraemic syndrome and complement factor H deficiency. Nephrol Dial Transplant (1999) 0.92
Regulation of the activity of platelet-bound C3 convertase of the alternative pathway of complement by platelet factor H. Proc Natl Acad Sci U S A (1987) 0.88
The role of the endothelium in hemolytic uremic syndrome. J Nephrol (2002) 0.86
Factor H--US? Nephrol Dial Transplant (1998) 0.85
Complement factor H and haemolytic uraemic syndrome. Lancet (2002) 0.81
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 7.69
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Preventing microalbuminuria in type 2 diabetes. N Engl J Med (2004) 6.41
The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int (2011) 6.21
Atypical hemolytic-uremic syndrome. N Engl J Med (2009) 5.66
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 4.51
Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy. Nat Genet (2010) 3.99
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 3.82
Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol (2012) 3.79
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 3.78
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol (2005) 3.57
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet (2005) 3.52
How does proteinuria cause progressive renal damage? J Am Soc Nephrol (2006) 3.46
Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol (2004) 3.41
Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med (2009) 3.24
Hemolytic uremic syndrome. J Am Soc Nephrol (2005) 3.19
Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med (2011) 3.17
Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol (2011) 3.13
Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int (2009) 3.12
Delayed graft function in kidney transplantation. Lancet (2004) 3.06
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood (2009) 2.97
Decision time for pancreatic islet-cell transplantation. Lancet (2008) 2.91
Familial haemolytic uraemic syndrome and an MCP mutation. Lancet (2003) 2.79
Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet (2007) 2.79
Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet (2003) 2.71
Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA (2005) 2.69
Renal progenitors: an evolutionary conserved strategy for kidney regeneration. Nat Rev Nephrol (2013) 2.66
MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N Engl J Med (2011) 2.65
Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature (2011) 2.64
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol (2011) 2.60
Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells (2008) 2.51
Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest (2009) 2.49
Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol (2008) 2.48
Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood (2007) 2.46
Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis (2004) 2.43
Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet (2003) 2.43
Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol (2010) 2.42
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol (2006) 2.37
Posterior retroperitoneoscopic adrenalectomy--results of 560 procedures in 520 patients. Surgery (2006) 2.35
Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int (2005) 2.32
MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition. J Am Soc Nephrol (2012) 2.26
Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer (2004) 2.20
Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy. Hypertension (2009) 2.20
Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol (2008) 2.17
Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis (2006) 2.17
Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes (2002) 2.12
Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet (2002) 2.12
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens (2007) 2.12
Pheochromocytoma: presentation, diagnosis and treatment. J Hypertens (2006) 2.09
Complement inhibitor factor H binding to Lyme disease spirochetes is mediated by inducible expression of multiple plasmid-encoded outer surface protein E paralogs. J Immunol (2002) 2.06
Insulin-like growth factor-1 sustains stem cell mediated renal repair. J Am Soc Nephrol (2007) 2.02
Factor H family proteins and human diseases. Trends Immunol (2008) 2.02
Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol (2007) 2.00
Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol (2013) 2.00
Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol (2007) 2.00
Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol (2008) 1.99
Complement resistance of Borrelia burgdorferi correlates with the expression of BbCRASP-1, a novel linear plasmid-encoded surface protein that interacts with human factor H and FHL-1 and is unrelated to Erp proteins. J Biol Chem (2003) 1.99
Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int Suppl (2005) 1.96
Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.. Radiology (2002) 1.96
Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood (2008) 1.95
An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum Mol Genet (2010) 1.95
Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol (2007) 1.94
Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int (2003) 1.91
Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. J Am Soc Nephrol (2008) 1.89
STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol (2012) 1.89
Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds to short consensus repeats 8-11 of factor H. J Immunol (2002) 1.87
Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol (2010) 1.87
von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood (2002) 1.85
Imaging of the porous ultrastructure of the glomerular epithelial filtration slit. J Am Soc Nephrol (2010) 1.85